---
title: "Troglitazone - Diabetes Mellitus, Type 2 - 2"
sidebar: mydoc_sidebar
permalink: db00197-mesh-d003924-2.html
toc: false 
---


Path ID: `DB00197_MESH_D003924_2`
{% include image.html url="images/db00197-mesh-d003924-2.png" file="db00197-mesh-d003924-2.png" alt="db00197-mesh-d003924-2" %}

## Concepts

|------------|------|---------|
| Identifier | Name | Type    |
|------------|------|---------|
| <a href="https://identifiers.org/MESH:D000077288">MESH:D000077288 </a> | Troglitazone | Drug |
| <a href="https://identifiers.org/UniProt:P37231">UniProt:P37231 </a> | Peroxisome proliferator-activated receptor gamma | Protein |
| <a href="https://identifiers.org/InterPro:IPR000003">InterPro:IPR000003 </a> | Retinoid X receptor/HNF4 | GeneFamily |
| <a href="https://identifiers.org/UniProt:P15090">UniProt:P15090 </a> | Fatty acid-binding protein, adipocyte | Protein |
| <a href="https://identifiers.org/GO:0060612">GO:0060612 </a> | adipose tissue development | BiologicalProcess |
| <a href="https://identifiers.org/MESH:D005230">MESH:D005230 </a> | Fatty Acids, Nonesterified | ChemicalSubstance |
| <a href="https://identifiers.org/HP:0000855">HP:0000855 </a> | Insulin resistance | PhenotypicFeature |
| <a href="https://identifiers.org/MESH:D003924">MESH:D003924 </a> | Diabetes Mellitus, Type 2 | Disease |
|------------|------|---------|

## Relationships


NOTE: predicates are annotated in <a href="https://github.com/biolink/biolink-model/releases/tag/v1.3.0">Biolink Model (v1.3.0)</a>

|---------|-----------|---------|
| Subject | Predicate | Object  |
|---------|-----------|---------|
| Troglitazone | INCREASES ACTIVITY OF | Peroxisome Proliferator-Activated Receptor Gamma |
| Peroxisome Proliferator-Activated Receptor Gamma | MOLECULARLY INTERACTS WITH | Retinoid X Receptor/Hnf4 |
| Retinoid X Receptor/Hnf4 | INCREASES ACTIVITY OF | Fatty Acid-Binding Protein, Adipocyte |
| Fatty Acid-Binding Protein, Adipocyte | POSITIVELY REGULATES | Adipose Tissue Development |
| Adipose Tissue Development | NEGATIVELY CORRELATED WITH | Fatty Acids, Nonesterified |
| Fatty Acids, Nonesterified | CONTRIBUTES TO | Insulin Resistance |
| Insulin Resistance | MANIFESTATION OF | Diabetes Mellitus, Type 2 |
|---------|-----------|---------|

Comment: Troglitazone was withdrawn from the United States market in 2000 due to risk of hepatotoxicity.

Reference: 
  - [https://go.drugbank.com/drugs/DB00197#mechanism-of-action](https://go.drugbank.com/drugs/DB00197#mechanism-of-action)
  - [https://en.wikipedia.org/wiki/Thiazolidinedione](https://en.wikipedia.org/wiki/Thiazolidinedione)
  - [https://www.uniprot.org/uniprot/P37231#function](https://www.uniprot.org/uniprot/P37231#function)
  - [https://www.uniprot.org/uniprot/P15090#function](https://www.uniprot.org/uniprot/P15090#function)
  - [https://en.wikipedia.org/wiki/Type_2_diabetes](https://en.wikipedia.org/wiki/Type_2_diabetes)
